肿瘤免疫治疗新靶点TIGIT研究进展

Research progress on TIGIT,a new target for tumor immunotherapy

免疫治疗已经成为肿瘤治疗一种新的治疗模式,在多种类型肿瘤治疗中获得显著的疗效,但仍有大量患者并没有从中获益,这些患者往往具有肿瘤突变负荷低、新抗原负荷低、肿瘤微环境免疫抑制等特征。研究人员认为肿瘤可能存在其他未知免疫抑制途径。TIGIT是一种新的免疫抑制分子,在多种肿瘤中可发现其表达异常,多个研究表明TIGIT能够导致免疫细胞功能障碍,与肿瘤进展、预后不良相关,通过阻断TIGIT可以逆转免疫细胞功能衰竭,发挥抗肿瘤效应,有望成为新一代免疫治疗靶点。

Immunotherapy has been regarded as a new method for the treatment of tumors,and has achieved significant efficiency in many types of tumors,but there are still a large number of patients who have not benefited from it.These patients often have characteristics of low tumor mutational load,low new antigen load,and tumor microenvironment immunosuppression.Researchers believe that there are many other unknown immunosuppressive ways in tumors.TIGIT is a new immunosuppressive molecule,and its abnormal expression can be found in a variety of tumors.Many studies have shown that TIGIT plays an important role in immune cell dysfunction,which is related to tumor progression and poor prognosis.Blocking TIGIT can reverse immune cell failure and exert anti-tumor effect,which is expected to act as a new generation of immunotherapy target in the future.